Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SDHB | P21912 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | STAT1 | P42224 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29698972 | 0.81 | NPY5R (0.40) | SDHBHPGDMEN1S1PR4LMNA | |
| SCHEMBL29699125 | 0.81 | SDHB (0.34) | SDHBHPGDMEN1S1PR4LMNA | |
| SCHEMBL30368827 | 0.78 | PIK3CG (0.38) | SDHBHPGDMEN1S1PR4LMNA | |
| SCHEMBL21410000 | 0.78 | PIK3CG (0.38) | SDHBHPGDMEN1S1PR4LMNA | |
| SCHEMBL30810462 | 0.78 | CCNE1 (0.62) | — | |
| SCHEMBL30549156 | 0.77 | PTK2 (0.37) | SDHBHPGDMEN1S1PR4LMNA | |
| SCHEMBL10555889 | 0.77 | SDHB (0.49) | SDHBHPGDMEN1S1PR4LMNA | |
| SCHEMBL25428909 | 0.76 | MAPT (0.50) | HPGDLMNAHTTNPSR1ALDH1A1 | |
| SCHEMBL25239800 | 0.76 | SDHB (0.46) | SDHBHPGDMEN1S1PR4LMNA | |
| SCHEMBL30397985 | 0.76 | SDHB (0.46) | SDHBHPGDMEN1S1PR4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130022594-A1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-24 | — | — | US | disclosed |
| US-20130017194-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017194-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | SDHB 3248/4885HPGD 3082/4885MEN1 2541/4885 |
| US-20130022594-A1 | SELECTIVE FAK INHIBITORS | PTK2, CTTN, SRC | SDHB 3412/4885HPGD 3306/4885MEN1 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.